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Abstract: Atrial fibrillation (AF) is associated with a fivefold increase in the risk of stroke. The 
Phase III ROCKET AF (Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared 
with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) 
trial showed that rivaroxaban, an oral, direct Factor Xa inhibitor, was noninferior to warfarin 
for the reduction of stroke or systemic embolism in patients with AF. Compared with warfarin, 
rivaroxaban significantly reduced rates of intracranial and fatal hemorrhages, although not 
rates of bleeding overall. XANTUS (Xarelto® for Prevention of Stroke in Patients with Atrial 
 Fibrillation) is a prospective, international, observational, postauthorization, noninterventional 
study designed to collect safety and efficacy data on the use of rivaroxaban for stroke preven-
tion in AF in routine clinical practice. The key goal is to determine whether the safety profile of 
rivaroxaban established in ROCKET AF is also observed in routine clinical practice. XANTUS is 
designed as a single-arm cohort study to minimize selection bias, and will enroll approximately 
6,000 patients (mostly from Europe) with nonvalvular AF prescribed rivaroxaban, irrespective 
of their level of stroke risk. Overall duration of follow-up will be 1 year; the first patient was 
enrolled in June 2012. Similar studies (XANTUS-EL [Xarelto® for Prevention of Stroke in 
Patients with Nonvalvular Atrial Fibrillation, Eastern Europe, Middle East, Africa and Latin 
America] and XANAP [Xarelto® for Prevention of Stroke in Patients with Atrial Fibrillation 
in Asia-Pacific]) are ongoing in Latin America and Asia-Pacific. Data from these studies will 
supplement those from ROCKET AF and provide practical information concerning the use of 
rivaroxaban for stroke prevention in AF.
Keywords: rivaroxaban, anticoagulants, atrial fibrillation, stroke, Phase IV
Introduction
Atrial fibrillation (AF) is the most common sustained arrhythmia reported in clinical 
practice,1 and is associated with a fivefold or greater increase in the risk of stroke.2 
Although effective for stroke risk reduction in AF, vitamin K antagonists (VKAs) have 
significant clinical limitations and are underused in practice.3,4 The past 2 years have 
seen the approval of three non-VKA oral anticoagulants (NOACs) for stroke  prevention 
in AF: dabigatran, rivaroxaban, and apixaban, all of which are now  recommended in 
guidelines.5,6
Rivaroxaban
Rivaroxaban was the first oral, direct Factor Xa inhibitor to receive approval from regu-
latory authorities for stroke prevention in patients with AF, based mainly on the results 
Vascular Health and Risk Management 2014:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
426
camm et al
of the Phase III ROCKET AF trial (Rivaroxaban Once-Daily 
Oral Direct Factor Xa Inhibition Compared with Vitamin K 
Antagonism for Prevention of Stroke and Embolism Trial in 
Atrial Fibrillation; NCT00403767).7 In addition, rivaroxaban 
has received approval in many countries, including the US8 
and the countries of the European Union,9 and for use in 
several other different thromboembolic conditions.9
Rivaroxaban has no requirement for routine coagula-
tion monitoring and has few drug–drug interactions.10–12 
The drug undergoes renal clearance of active compound in 
plasma of approximately 33%.11 Pharmacokinetic analyses 
from two Phase II evaluations of rivaroxaban for treatment 
of deep-vein thrombosis and prevention of recurrent venous 
thromboembolism in patients with deep-vein thrombosis13,14 
were adapted to provide estimates of rivaroxaban exposure 
in simulated patients with AF;15 these analyses indicated 
that 20 mg once daily would be an appropriate dosage for 
stroke prevention in AF. Furthermore, patients with moderate 
renal impairment (creatinine clearance of 30–49 mL/minute) 
would experience the same exposure if the dose of rivaroxa-
ban was reduced to 15 mg once daily. Hence, 20 mg once 
daily (reduced to 15 mg once daily in patients with moderate 
renal impairment) was selected for Phase III evaluation in 
the ROCKET AF trial.16
ROCKET AF
In the Phase III ROCKET AF study, rivaroxaban was com-
pared with dose-adjusted warfarin for the prevention of stroke 
and systemic embolism in high-risk patients with nonvalvular 
AF.7 Rivaroxaban was noninferior to warfarin with regard 
to rates of stroke or systemic embolism (intention-to-treat 
analysis). Overall bleeding rates for rivaroxaban versus war-
farin were similar for major or nonmajor clinically relevant 
bleeding, although gastrointestinal bleeding was increased 
with rivaroxaban. However, rivaroxaban therapy resulted 
in significantly fewer fatal bleeding events and intracranial 
hemorrhages than warfarin.7 Efficacy and safety results are 
shown in Tables S1 and S2, respectively.
Postauthorization studies
Phase III clinical trials are generally registration trials that 
support marketing approval by the regulatory authorities. 
Such trials must meet strict design requirements to ensure 
well-defined inclusion and exclusion criteria, strict protocol 
adherence, appropriate clinical endpoints, and statistical 
validity. These requirements mean that event rates with 
the experimental drug and the patient characteristics in the 
clinical trial population may or may not fully reflect those 
observed in the broad range of patients seen in routine care. 
Therefore, postauthorization studies are needed to explore the 
efficacy and safety of a new agent in routine clinical practice. 
This is particularly true for oral anticoagulants, for which 
factors that could potentially influence outcomes (eg, adher-
ence, persistence, comorbidities) might vary between the 
strict environment of a clinical trial and that of real-world 
therapy in routine practice.
XANTUS
objectives and rationale
XANTUS (Xarelto® for Prevention of Stroke in Patients 
with Atrial Fibrillation; NCT01606995) is a prospective, 
 international, postauthorization, observational, noninter-
ventional Phase IV study in patients with nonvalvular AF 
prescribed rivaroxaban for prevention of stroke in routine 
practice. This paper describes the objectives, design, and 
 protocol for the XANTUS study, as well as key limitations.
Because the XANTUS study is intended to assess the use 
of rivaroxaban in routine, real-world clinical practice, study 
procedures will not interfere with the clinical management 
of patients or with the prescribing behaviors of attending 
physicians. In contrast to ROCKET AF, patients with non-
valvular AF may be included in XANTUS regardless of 
their risk of stroke, although it is presumed that they will be 
prescribed rivaroxaban in accordance with the appropriate 
prescribing information. Data collected will include risk 
assessment, bleeding events, thromboembolic events, and 
adverse events (AEs) that occur in patients with nonvalvular 
AF receiving rivaroxaban in routine care according to the 
local marketing authorization. Information on the clinical 
management of these events will also be collected.
The key goal for XANTUS is to confirm the safety profile 
of rivaroxaban across the broad range of patient risk profiles 
encountered in the setting of routine clinical practice. This 
will include assessment of rivaroxaban’s safety in patients 
at increased risk of thromboembolic or bleeding events. It 
is also expected that the data collected during the course of the 
study will provide a comprehensive overview of the outcomes 
associated with rivaroxaban therapy and factors influencing 
its use in the clinical management of stroke prophylaxis in 
AF, across different geographic regions, care settings, patient 
populations, and health care systems.
XANtuS study program
The XANTUS study described below is the prototype for a 
series of four separate Phase IV studies designed to cover 
different global regions (Table 1), and which collectively 
comprise the XANTUS program. It is intended that all four 
of these studies will use the same protocol and will contribute 
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results to the same central database. A pooled analysis is 
also planned.
design and protocol
XANTUS is designed as a single-arm observational, non-
interventional cohort study (Figure 1). Overall duration of 
follow-up for each patient will be 1 year, with intermediate 
follow-up visits at approximately 3-month intervals.
Study protocol
Patient population, enrollment, and follow-up
Eligible patients comprise men and women aged 18 years or 
older with nonvalvular AF who start rivaroxaban therapy to 
reduce the risk of stroke or systemic embolism and who have 
provided written informed consent. To reduce selection bias, 
all patients at least 18 years old presenting with nonvalvular 
AF will be screened sequentially and documented in an anon-
ymous log file independent of therapy. Patients prescribed 
rivaroxaban will be eligible for the study, and all such patients 
must be enrolled consecutively. If a patient is not eligible for 
any reason (eg, refusal to provide consent), then the reason 
must be documented in the log file.  Contraindications to 
rivaroxaban therapy should be considered according to local 
marketing authorizations. For XANTUS, enrollment will 
take place at up to 300 sites, each of which should enroll a 
minimum of 20 and a maximum of 60 patients. Sites must 
be able to capture data electronically and provide long-term 
follow-up for patients.
After the initial screening visit, follow-up visits will 
occur at the time of hospital discharge, if applicable, 
and  approximately every 3 months thereafter. The over-
all follow-up period will be 1 year, and will conclude 
with a final patient visit. For patients who discontinue 
therapy before the end of the 1-year follow-up, the 
observation period will end approximately 30 days after 
the last dose of rivaroxaban (Figure 1 and  Supplementary 
material).
drug administration
The decision to prescribe rivaroxaban is at the sole discretion 
of the treating physician, including the dose and duration 
of rivaroxaban therapy. Any prior use of an anticoagulant 
will be documented in the case report form (CRF) and all 
concomitant medications or other therapies will also be 
Table 1 clinical studies comprising the XANtuS program
Studya XANTUSb XANTUS-EL XANAPc XANTUS-CN
NCT identifier Nct01606995 Nct01800006 Nct01750788 Not yet available
Estimated enrollment 6,000 At least 10,000 patients expected across all three studies
First patient, first visit (date) June 12, 2012 July 18, 2013 February 6, 2013 In planning
Primary geographic region European union, plus 
enrollment in canada
Eastern Europe, 
Eastern Mediterranean, 
Middle East, latin America
Asia-Pacific People’s Republic 
of china
Notes: aAll studies will use the same design, database, and adjudication procedures; bthe parent study and subject of this paper; cthe East Asia subanalysis of RocKEt AF 
demonstrated that the 20 mg once-daily dose did not need to be adjusted in patients in this region, and that results from the East Asian population were consistent with 
those from the overall study.17
Abbreviations: XANtuS, Xarelto® for Prevention of Stroke in Patients with Atrial Fibrillation; XANtuS-El, Xarelto® for Prevention of Stroke in Patients with Nonvalvular 
Atrial Fibrillation, Eastern Europe, Middle East, Africa and latin America; XANAP, Xarelto® for Prevention of Stroke in Patients with Atrial Fibrillation in Asia-Pacific; 
XANtuS-cN, Xarelto® for Prevention of Stroke in Patients with Atrial Fibrillation – china.
Study population:  
Patients with
nonvalvular AF
(n=6,000) in
Europe who start
treatment with
rivaroxaban to
prevent stroke or
non-CNS systemic
embolism    
 
 
 
Rivaroxaban;
duration of
treatment at
the discretion
of the
attending
physician  
Investigators to collect data at initial visit, at
hospital  discharge (if applicable), and quarterlya 
Final visit
1 yearb
 
 
Figure 1 XANtuS study design, an observational, single-arm cohort study. the objective is to collect real-life data on adverse events, bleeding, thromboembolic events, and 
mortality in patients with nonvalvular AF treated with rivaroxaban. the same basic design will be used for all studies in the XANtuS program.
Notes: aProtocol does not define exact referral dates for follow-up visits (every 3 months recommended); bin patients discontinuing rivaroxaban before 1 year, the end of 
the observation period is 30 days after the last dose. XANTUS (clinicaltrials.gov: NCT01606995).
Abbreviations: AF, atrial fibrillation; CNS, central nervous system; XANTUS, Xarelto® for Prevention of Stroke in Patients with Atrial Fibrillation.
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documented. For patients withdrawing from the study, the 
reasons and any follow-on therapy are to be documented in 
the CRF. Temporary interruptions of rivaroxaban therapy 
will also be documented.
data and information to be collected
Baseline data
Baseline demographics will be collected at the initial visit 
and will include:
•	 age, sex, ethnicity, smoking history, and alcohol use
•	 previous therapies or interventions to treat AF, including 
cardioversion and ablation
•	 prior medication (medication taken before study com-
mencement), including any prior use of anticoagulants
•	 concomitant medications (ie, medications taken in addi-
tion to rivaroxaban at time of commencing rivaroxaban 
therapy)
•	 vital signs and laboratory tests, if performed as part of 
routine care
•	 other medical history at baseline, such as bleeding 
diathesis or risk factors for stroke in AF (eg, hyperten-
sion, diabetes, heart failure, prior stroke)
•	 stroke and bleeding risk profiles; risk profiles will be 
based on such risk scores as CHADS
2
 (Congestive heart 
failure, Hypertension, Age, Diabetes mellitus, Stroke)18 
CHA
2
DS
2
-VASc (Vascular disease, Age, Sex category),19 
or HAS-BLED (Hypertension, Abnormal liver/renal 
function, Stroke history, Bleeding predisposition, Labile 
international normalized ratios, Elderly, Drug/alcohol 
usage).20
Study outcomes to be captured
Primary outcomes
The primary outcomes to be collected are those that can 
assess and estimate the safety of rivaroxaban in routine 
practice. These will be recorded as AEs or serious AEs, and 
include major bleeding, defined as in ROCKET AF,7 all-
cause mortality, and any other AEs and serious AEs. The 
sites of major bleeding events will also be captured. Outcome 
definitions are provided in the Supplementary material.
Secondary outcomes
•	 Symptomatic thromboembolic events
•	 Nonmajor bleeding events, defined as any bleeding event 
that does not meet the criteria for a major hemorrhage
•	 Rates of AEs and serious AEs across patients with 
different baseline risk profiles for stroke or bleeding 
(eg, CHADS
2
, CHA
2
DS
2
-VASc, or HAS-BLED). 
Rates of AEs and serious AEs will also be evaluated 
within other important medical subgroups (defined at base-
line). These include, among others:
•	 age, sex, and ethnicity
•	 body mass index
•	 prior use of oral anticoagulants
•	 concomitant medications
•	 creatinine clearance
•	 baseline type of AF
•	 prior stroke, transient ischemic attack (TIA), or 
non-systemic embolism.
other outcomes
These include the use of concomitant medications initiated 
any time after start of rivaroxaban therapy. Over-the-counter 
medications such as acetylsalicylic acid should also be 
included. Treatment satisfaction is to be reported by patients 
using standardized questionnaires completed at quarterly 
intervals. Patients who received a VKA in the 4 weeks prior 
to enrolling in the study will also be asked to complete a 
questionnaire at the initial visit. The questionnaires used 
will be translated, and validated with versions of either the 
Anti-clot Treatment Scale or the Treatment Satisfaction 
Questionnaire for Medication. Also included are health 
care-resource use, including health care visits, length of 
stay for hospitalizations, and nurse visits in the community 
(eg, for administration of a parenteral anticoagulant), details 
of interventions and how they were managed, and reasons 
for any switch from or interruption of rivaroxaban therapy, 
including assessment of persistence with therapy
Reporting of adverse events
AEs and serious AEs will be recorded on the AE report form 
that is appended to the CRF. The AE report form will docu-
ment the seriousness, duration, actions taken, outcomes, and 
relation to rivaroxaban therapy for each AE. For patients who 
discontinue rivaroxaban early, documentation concerning AEs 
will also cover the 30-day period after cessation of therapy.
Additionally, the manner in which bleeding and 
 thromboembolic events are managed in the routine prac-
tice setting will be recorded. This includes any use of 
 thrombolytics or surgical intervention after ischemia or 
use of prohemostatic agents (eg, prothrombin-complex 
 concentrates) for major bleeding.
These cumulative data will provide a comprehensive 
overview of the use of rivaroxaban in routine practice and 
of how clinical events arising during stroke prophylaxis in 
AF are managed in this setting.
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Statistical considerations
overview
The main goal of the XANTUS study is to develop esti-
mates of the rates of treatment-emergent AEs arising in 
routine clinical practice. AEs are considered treatment-
emergent when they occur from the day of the first dose of 
 rivaroxaban, and up to 2 days after the last dose in the event 
of discontinuation.
Statistical analyses will be descriptive, exploratory, and 
generally limited to frequency tables or summary statistics 
(eg, means ± standard deviation or medians ± quartiles), 
eg, for demographic data. The primary analysis population 
will be the full safety population, defined as all patients 
who have taken at least one dose of rivaroxaban, although 
analyses will be performed not only for the full study sample 
but also for each participating country where numbers are 
sufficient for statistical analysis. Each of the four studies in 
the XANTUS program will report separately, but there will 
also be a prespecified pooled analysis. In addition, results 
will be derived for medically relevant subgroups, eg, elderly 
patients, patients with renal impairment or prior stroke/TIA, 
and patients with different stroke-risk profiles, eg, CHADS
2
 
or CHA
2
DS
2
-VASc categories. The combined data set is also 
expected to permit the determination of regional differences 
in the use of rivaroxaban and to allow the investigators to 
identify any differences in treatment approaches for  different 
ethnicities.
Presentation of events of interest
Both raw incidence proportions (patients with events/number 
of treated patients) and incidence rates (eg, patients with 
events per 100 patient-years) will be presented. Each such 
estimate will be presented with corresponding 95% confi-
dence intervals (CIs). In addition, Kaplan–Meier plots will 
be generated to show the time course up to the first event 
of interest.
Rationale for sample size
The overall incidence of major bleeding in ROCKET 
AF was 5.6% (395 of 7,111) over a maximum follow-up 
period of 1,263 days. Over the first year, 3.5% (250 of 
7,111) of patients experienced a major bleeding event, and 
it is assumed that this figure is representative of the rate of 
major bleeding in patients receiving rivaroxaban in a real-
world setting. A sample size of 5,000 patients would yield a 
95% CI of 3.008–4.047, assuming a rate of major bleeding 
of 3.5%. In other words, assuming an underlying event rate 
of 3.5%, the CI would be #1.1% with a probability of 95%. 
A lower event rate with the same sample size would result in 
a narrower CI. This is considered sufficiently precise for the 
purposes of the study. However, because it was also assumed 
that 20% of patients would be unevaluable, target enrollment 
was increased to 6,000 patients.
data integrity and quality
All outcome variables and covariates will be recorded on a 
standardized CRF. Reporting bias will be minimized by onsite 
quality reviews to verify source data from at least 10% of the 
sites. Furthermore, 50% of the sites will receive random visits 
to monitor study conduct. Selection bias will be minimized 
by requiring investigators to document consecutive patients 
prescribed rivaroxaban, with no omissions.
data management and administrative 
organization
The parent XANTUS study is a postauthorization safety 
study funded by Bayer HealthCare. Each of the four studies 
in the program will have its own steering committee, and the 
program as a whole will be overseen by an executive steering 
committee. Major events, specifically major bleeding, stroke, 
systemic embolism, TIA, and myocardial infarction, will be 
adjudicated centrally by the same adjudication committee 
for all four studies, blinded to individual patient data. Data 
verification at study sites should facilitate identification of 
any relevant outcomes not submitted for adjudication. The 
study will use one centralized database to receive results, and 
results from all four studies in the program will be stored in 
the same database.
Discussion
Registration clinical trials, such as ROCKET AF, are required 
to mandate strict inclusion and exclusion criteria and to 
enforce tight control of both the intervention therapy and the 
comparator. In the case of ROCKET AF (and other trials), 
this was further complicated by the double-blind, double-
dummy protocol. The advantage of this approach is that the 
efficacy and safety of rivaroxaban relative to warfarin are 
now well established.7 Conversely, there are limited data 
concerning the clinical utility of rivaroxaban for long-term 
use, in contrast to the strictly controlled environment of a 
Phase III clinical trial.
Noninterventional studies and registries have a  pivotal 
role in conf irming the eff icacy and safety of newly 
approved interventions across the wide range of patients 
(demographics, comorbidities, health care access, etc) 
treated in routine practice, an environment in which control 
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of patient therapy is often not as strict as in a clinical trial. 
For example, the recently completed XAMOS (XArelto in 
the prophylaxis of post-surgical venous thromboembolism 
after elective Major Orthopaedic Surgery of hip or knee) 
study21 was a noninterventional study in which the use of 
rivaroxaban in routine practice for the prevention of venous 
thromboembolism after elective hip or knee replacement 
was evaluated, although local standard of care was included 
as a comparator. The results confirmed the superior efficacy 
and similar safety of rivaroxaban, relative to the standard 
of care, reported in the Phase III RECORD (REgulation of 
Coagulation in ORthopedic surgery to prevent Deep venous 
thrombosis and pulmonary embolism) program.22
Noninterventional studies such as XAMOS or XANTUS 
and registries such as GARFIELD (Global Anticoagulant 
Registry in the FIELD)-AF,23 ORBIT-AF (Outcomes  Registry 
for Better Informed Treatment of Atrial Fibrillation),24 and 
the Dresden NOAC registry (NCT01588119) can go a long 
way toward meeting the need for real-world data on the 
efficacy and safety of rivaroxaban, and in particular confirm-
ing the safety of rivaroxaban in the routine practice setting. 
 Postauthorization studies for other NOACs are also in pro-
cess (eg, NCT01774370 [SPARK {Safety Study of Pradaxa 
in Atrial Fibrillation Patients by Regulatory Requirement of 
Korea}] and NCT01491178 for dabigatran).
Postauthorization studies, such as XANTUS, can also con-
tribute important additional information on various aspects 
of patient management in routine care. For  rivaroxaban, this 
might include the following:
•	 When bleeding events or strokes do occur in patients 
receiving rivaroxaban, how are they managed, particularly 
in the first few days after a stroke?
•	 What are the most common reasons for temporary inter-
ruptions of rivaroxaban therapy?
•	 How are cardioversion and ablation procedures 
managed?
•	 How is switching to a parenteral anticoagulant managed 
in practice (where relevant), and how is reinitiation of 
rivaroxaban therapy managed?
•	 How are conversions from/to conventional VKA treatment 
to/from rivaroxaban performed in routine practice? This 
may be of particular importance in light of the transient 
increase in events observed at the end of the ROCKET 
AF study period in patients transitioning from blinded 
rivaroxaban to open-label warfarin.
•	 Are there signals that either eff icacy or safety of 
 rivaroxaban in this real-world cohort differ markedly from 
the published experience in controlled clinical trials?
XANTUS will also provide useful information on factors 
that can affect patient compliance with therapy, potentially 
an important determinant of the effectiveness of stroke 
prophylaxis. The study may also contribute to optimizing 
management of patients at increased risk of both ischemic 
and hemorrhagic events, such as the use of various comedi-
cations, patients with renal impairment, and those who have 
experienced a prior stroke.
Uptake of NOACs into routine practice is expected 
to occur gradually after marketing approval is received. 
 However, if a study such as XANTUS was to include a com-
parator arm (eg, warfarin therapy), then the noninterventional 
aspects of such a nonrandomized study might result in 
patients most likely to experience difficulties with war-
farin therapy (eg, those at high risk of bleeding or poor 
 compliance) being those most likely to be prescribed 
rivaroxaban. Conversely, patients most likely to do well on 
therapy might be more likely to receive a VKA. This would 
inevitably result in a considerable degree of selection bias, 
and for this reason a single-arm cohort study was considered 
the most appropriate design. A limitation of this design is that 
any relative risk estimates are not feasible. In addition, the 
strictly limited data available for patients screened but not 
enrolled preclude any comparison of treatment-selection 
rationales. A further limitation is that because XANTUS is 
strictly an observational study, estimates of event rates will 
not be corrected or normalized for baseline characteristics or 
for different durations of rivaroxaban therapy. However, the 
prospective definition of events and outcomes to be captured 
is expected to enhance the accuracy with which events are 
recorded. Event rates within predefined baseline subgroups 
(eg, stroke-risk categories) will also be determined.
There are several practical questions concerning the 
management of certain events, such as ischemic stroke, 
in a patient receiving an NOAC. For example, should 
 thrombolytic therapy be used, and if so, what factors should 
be considered? Similarly, understanding the way in which 
bleeding events are managed will also be of use, including 
factors determining if and when such agents as prothrombin-
complex concentrates are used or when rivaroxaban can 
be restarted after an intracranial hemorrhage. XANTUS is 
expected to make a substantial contribution to answering such 
questions, and should show how clinicians are approaching 
this and other everyday clinical challenges.
Conclusion
XANTUS will provide a comprehensive data set to 
support the safety and clinical utility of rivaroxaban for 
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 stroke-risk reduction in patients with AF in routine practice 
(ie, beyond the strict confines of the randomized clinical trial 
environment). The study will also provide important insights 
into the management of AEs occurring in patients receiving 
rivaroxaban therapy, as well as factors that contribute to 
maximizing patient satisfaction and optimizing real-world 
outcomes.
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Supplementary material
Outcome definitions
Stroke
Stroke is defined as a new, sudden, focal neurologic deficit 
resulting from a presumed cerebrovascular cause that is not 
reversible within 24 hours and not due to a readily identifiable 
cause, such as a tumor or seizure.
Whenever possible, computed tomography scanning or 
magnetic resonance imaging should be used to assist in the 
classification. Stroke will be classified as:
•	 primary hemorrhagic – stroke with focal collections of 
intracerebral blood; hemorrhagic stroke will be recorded 
as bleeding and as stroke; note that subarachnoid, 
 subdural, and epidural hemorrhages will be recorded as 
bleeding events
•	 primary ischemic – stroke without focal collections of 
intracranial blood; hemorrhagic conversion of a primary 
ischemic infarction will be recorded
•	 uncertain – no imaging or autopsy data available.
Death within 30 days of stroke onset will be considered 
a fatal stroke.
transient ischemic attack
An event matching the definition for stroke but lasting less 
than 24 hours will be considered a transient ischemic attack 
(TIA). The duration of symptoms for a TIA will be recorded, 
as will the results of any imaging procedures. However, TIA 
events with neuroimaging documentation of a cerebral infarc-
tion in the appropriate location for the clinical syndrome will 
be recorded as an ischemic stroke.
Non-central nervous system systemic embolism
Non-central nervous system systemic embolism is 
defined as abrupt vascular insufficiency associated with 
clinical or radiologic evidence of arterial occlusion in 
the absence of other likely mechanisms (eg, trauma, 
atherosclerosis,  instrumentation). In the presence of 
atherosclerotic  peripheral vascular disease, diagnosis of 
embolism to the lower  extremities requires angiographic 
demonstration of abrupt arterial occlusion.
Myocardial infarction
Diagnosis of myocardial infarction will be considered 
relative to positive coronary angiography. In the absence of 
coronary angiography, myocardial infarction is defined as: 
clinical symptoms consistent with myocardial ischemia and 
cardiac biomarker elevation (troponin I or T, creatine-kinase 
muscle and brain subunit) greater than the site’s upper limit 
of normal; development of new pathologic Q waves in at least 
two contiguous leads on the electrocardiogram; or autopsy 
confirmation.
Major bleeding
This is defined as overt bleeding associated with:
•	 a fall in hemoglobin of $2 g/dL
•	 a transfusion of two or more units of packed red blood 
cells or whole blood
•	 occurrence at a critical site (intracranial, intraspinal, 
intraocular, pericardial, intra-articular, intramuscular with 
compartment syndrome, retroperitoneal)
•	 death.
Withdrawal from study
Patients may withdraw from the study at any time, and are 
not required to provide a reason. No patient will be disad-
vantaged by withdrawing.
However, because this is a noninterventional study, 
withdrawal from the study is independent of the patient’s 
particular therapy. Where a patient discontinues therapy 
Table S1 Primary efficacy results for ROCKET AF
Study  
population and  
analysis period
Median  
follow-up  
(days)
Rivaroxaban Warfarin Hazard ratio  
(95% CI)b
P-value
na Event rate  
(%/year)
na Event rate  
(%/year)
Noninferiority Superiority
Per protocol on  
treatment
590 6,958 1.7 7,004 2.2 0.79 (0.66–0.96) ,0.001 –
Safety on  
treatmentc
590 7,061 1.7 7,082 2.2 0.79 (0.65–0.95) – 0.02
Intention-to-treatd 707 7,081 2.1 7,090 2.4 0.88 (0.75–1.03) ,0.001 0.12
Notes: From Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.1 copyright © 2011 Massachusetts 
Medical Society. Reprinted with permission from Massachusetts Medical Society. aNumber of patients; bhazard ratio is for rivaroxaban versus warfarin; csafety population included all 
patients who received at least one dose of study medication; on-treatment analyses evaluated all events occurring while patients were receiving study medication or within 2 days 
of permanent discontinuation; dintention-to-treat follow-up was until notification of study termination. ROCKET AF (clinicaltrials.gov: NCT00403767).
Abbreviations: CI, confidence interval; ROCKET AF, Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of 
Stroke and Embolism trial in Atrial Fibrillation.
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prematurely, follow-up will be documented until 30 days 
after the discontinuation of treatment.
Every effort will be made to ascertain the rea-
son for withdrawal from the study or for premature 
Table S2 Rates of bleeding outcomes in RocKEt AF
Outcome Rivaroxaban Warfarin Hazard ratio  
(95% CI)a
P-value
Events  
n (%)
Event rate  
(%/year)
Events  
n (%)
Event rate  
(%/year)
Principal safety outcome  
(major + nonmajor clinically  
relevant bleeding)
1,475 (20.7) 14.9 1,449 (20.3) 14.5 1.03 (0.96–1.11) 0.44
Major bleeding
 Any 395 (5.6) 3.6 386 (5.4) 3.4 1.04 (0.90–1.20) 0.58
 decrease in Hb $2 g/dl 305 (4.3) 2.8 254 (3.6) 2.3 1.22 (1.03–1.44) 0.02
 transfusion 183 (2.6) 1.6 149 (2.1) 1.3 1.25 (1.01–1.55) 0.04
 critical bleedingb 91 (1.3) 0.8 133 (1.9) 1.2 0.69 (0.53–0.91) 0.007
Fatal bleeding 27 (0.4) 0.2 55 (0.8) 0.5 0.50 (0.31–0.79) 0.003
Intracranial hemorrhage 55 (0.8) 0.5 84 (1.2) 0.7 0.67 (0.47–0.93) 0.02
Notes: From Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.1 copyright © 2011 
Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. aHazard ratio is for rivaroxaban versus warfarin; bcritical organ bleeding 
refers to bleeding in intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular (with compartment syndrome), or retroperitoneal locations. ROCKET AF 
(clinicaltrials.gov: NCT00403767).
Abbreviations: CI, confidence interval; Hb, hemoglobin; ROCKET AF, Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for 
Prevention of Stroke and Embolism trial in Atrial Fibrillation.
discontinuation of therapy; this will be recorded in the 
case report form.
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